New GnRH blocker degarelix quickly suppresses levels of testosterone

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 6
Volume 17
Issue 6

ORLANDO-In a phase III study, the investigational GnRH blocker degarelix (Ferring Pharmaceuticals) significantly reduced testosterone levels within 3 days in more than 96% of study patients, Laurence Klotz, MD, of the University of Toronto, reported at AUA 2008. The fast effect on testosterone levels was close to the immediate effect achieved with surgery, he said.

ORLANDO-In a phase III study, the investigational GnRH blocker degarelix (Ferring Pharmaceuticals) significantly reduced testosterone levels within 3 days in more than 96% of study patients, Laurence Klotz, MD, of the University of Toronto, reported at AUA 2008. The fast effect on testosterone levels was close to the immediate effect achieved with surgery, he said.

The 12-month randomized, open-label, parallel-group study compared monthly subcutaneous administration of degarelix with monthly injection of the LHRH agonist leuprolide depot 7.5 mg in hormone-dependent prostate cancer patients. The degarelix patients received 240 mg at baseline and then were randomized to receive 80 or 160 mg monthly.

By day 3, testosterone levels were suppressed to ≤ 0.5 ng/mL in 96.1% of patients in the degarelix arms vs 0% in the leuprolide arm. By day 14, 100% of degarelix patients achieved testosterone suppression to ≤ 0.5 ng/mL vs 18.2% on leuprolide. After 14 days, PSA levels had declined in the degarelix-treated patients by a median of 64% vs 18% for leuprolide.

Recent Videos
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
It may be crucial to test every patient for markers such as BRAF V600E mutations, NRG1 fusions, and KRAS G12C mutations to help manage pancreatic cancers.
4 KOLs are featured in this series.
Tanios S. Bekaii-Saab, MD, emphasizes the idea of moving targeted therapies to earlier lines of treatment to further improve outcomes in pancreatic cancer.